CN1116047C - Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process - Google Patents
Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process Download PDFInfo
- Publication number
- CN1116047C CN1116047C CN 00114614 CN00114614A CN1116047C CN 1116047 C CN1116047 C CN 1116047C CN 00114614 CN00114614 CN 00114614 CN 00114614 A CN00114614 A CN 00114614A CN 1116047 C CN1116047 C CN 1116047C
- Authority
- CN
- China
- Prior art keywords
- liver
- powder
- misgurni anguillicaudati
- protecting
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention utilizes loach to prepare various forms of foods for protecting liver functions and utilizes loach to separate out effective natural ingredients for preventing and curing hepatitis, such as polysaccharide, glucoprotein and polypeptide, to prepare a new medicine for preventing and curing hepatitis. Loach has the medicinal efficacy of invigorating the spleen, benefiting qi, protecting the liver, eliminating huang, clearing away heat and toxic materials, dissolving lumps and removing stasis. In order to fully develop the health care function and the medicinal value of loach resource, the present invention utilizes loach to prepare new natural biochemical medicines for preventing and curing hepatitis and liver function protecting foods with the advantages of specific chemical constitution, exact liver protection function, stable dose and dosage form and obvious prevention and cure effect.
Description
The present invention relates to utilize the Misgurni anguillicaudati preparation that the food of liver-protecting function is arranged, with and preparation method thereof.
Misgurni anguillicaudati (Misgurus angillicaudatus Cantor) is the Cobitidae animal, meat or all be used as medicine, and its main effect is that invigorating the spleen and replenishing QI, hepatoprotective remove Huang, heat-clearing and toxic substances removing, dissolving lump and resolving mass.Be recorded in Compendium of Material Medica and the documents such as " Chinese medicine voluminous dictionaries ".Folk remedy is treated diseases such as carbuncle, dysentery, sexual impotence with Misgurni anguillicaudati, also useful Misgurni anguillicaudati looses or Misgurni anguillicaudati soup treatment infectious hepatitis.The method of being introduced according to " Chinese medicine voluminous dictionary " is: after the Misgurni anguillicaudati oven dry, be developed into the end, and each 10 grams, every day three times is in order to the treatment infectious hepatitis.The shortcoming of this method is to need the existing food of existing system, and is edible inconvenient.So far do not see the relevant report that spells out the active component of treatment hepatitis in the Misgurni anguillicaudati as yet.And also do not utilize the product of the function of protecting and nourishing liver food that Misgurni anguillicaudati makes for raw material to appear on the market.China is the highest country of incidence of hepatitis rate in the world, and the patient who infects various hepatitis viruss is hundreds of millions of.The present invention utilizes Misgurni anguillicaudati to make significant new natural biochemical drug and the functional food for protecting liver of preventing and treating hepatitis of prevention effect in order fully to develop the health care and the medical value of Misgurni anguillicaudati resource.
Method of the present invention is: clean with the fresh and alive Misgurni anguillicaudati that clear water was fed 1～3 day, will make 50～500 order fine powders with pulverizer after these Misgurni anguillicaudati dryings, or further be processed into nano level micropowder.Also Misgurni anguillicaudati can be twisted into the meat slurry with meat grinder, add 0～10% protease (as: pepsin, trypsin, papain, Streptothrix protease E, protease V8 or E.C. 3.4.21.64 etc.), control pH=1～8.5, in 10～50 ℃ of following incubations 5～48 hours, separate, remove residue, 50～500 order fine powders are made with pulverizer in dry back, or this powder further is processed into nano level micropowder.Above-mentioned fine powder is as the primary raw material of functional food for protecting liver.Can be 1～98% Misgurni anguillicaudati dry powder (or its hydrolyzed solution) with liver-protecting function with this content, sneak into following batching: amyloid adjuvant 1～90%, as: flour, starch, oatmeal, Semen Glycines powder, Rhizoma amorphophalli powder, black sesame powder, Semen arachidis hypogaeae powder; Excipient and thickening agent 0～10%, as: starch, dextrin, sodium carboxymethyl cellulose, agar, gelatin, alginate jelly, pectin; Flavoring agent 0～5%, as: Sal, sugar, Mel, milk powder, chocolate, protein sugar, cyclamate, acesulfame potassium, glucide, monosodium glutamate, chicken essence, yeastex, vinegar, vinegar (acid) essence, five spice powder, Fructus Piperis powder, Zanthoxyli Bungeani powder, curry powder, Fructus Capsici powder, Herba Alii fistulosi, Rhizoma Zingiberis powder, Bulbus Allii powder, Herba Menthae; Vitamins 0～2%, as: vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, Citrin; Food coloring 0～3%, as: bean sauce, soy sauce, carotene, caramel color, chocolate pigment, coffee pigment, gardenin, Fructus Citri tangerinae pigment, sunset yellow; Edible essence 0～2%, as: lychee flavor, apple essence, flavoring pineapple essence, strawberry essence, honey peach essence, cocoanut flavour, milk flavour, beef flavor, chicken essence, coffee aroma; Antiseptic 0～1%, as: benzoate, mud moor gold ester, antibacterial peptide, sorbate.The various forms of functional food such as dry powder that can be made into special-shaped sheet, sugar pill, cookies, cake, instant noodles, oral liquid, electuary, medicated porridge paste or use for mixing batter.Effect of the present invention is as follows: 1.1 couples of carbon tetrachloride (CCl of the mucous liver protection effect of 1 Misgurni anguillicaudati homogenate and Misgurni anguillicaudati
4) cause the inhibitory action of mouse liver injury
Get 48 of male mices, divide equally 6 groups at random: normal control group, normal saline group (NS), Misgurni anguillicaudati homogenate group (LS), Misgurni anguillicaudati mucus group (LM), bifendate group (DDB) and LONGDAN XIEGAN WAN group (LD) by body weight.Except that the normal control group,, weigh after 2 hours in last administration in the 6th day for all the other 6 groups, make it to poison by the dosage lumbar injection 0.2% carbon tetrachloride paraffin oil solution of 10ml/kg.Clean food is after 16 hours, broken end is got hematometry serum glutamic pyruvic transminase (ALT) and glutamic oxaloacetic transaminase, GOT (AST) activity, get liver and weigh, detect lipid peroxide (LPO) content in the hepatic tissue, malonaldehyde (MDA) content in the liver weight of unit of account body weight and the hepatic tissue.Result's (table 1) shows that carbon tetrachloride can make transaminase activity in the mice serum and the LPO content in the hepatic tissue significantly raise, and makes the liver enlargement.And that Misgurni anguillicaudati homogenate and Misgurni anguillicaudati mucus all can obviously suppress in the mice serum that carbon tetrachloride raises the LPO content regulating liver-QI in transaminase activity, the hepatic tissue is swollen.
Table 1 medicine causes inhibitory action (n=8, the group dosage Serum ALT serum AST AST/ALT liver MDA liver weight/body weight of x ± SD) of mouse liver injury to carbon tetrachloride (CCl4)
/ mgkg-1 * d/UL-1/UL-1/nmolg-1/gkg-1 normal control---188 ± 47 286 ± 38 1.52 25.8 ± 3.7 35.2 ± 5.1NS+CCl4 150 * 6 896 ± 33##, 579 ± 87##, 0.65 40.6 ± 4.5##, 47.2 ± 1.8##LS+CCl4 150 * 6 439 ± 97
*358 ± 94
*0.82 35.2 ± 4.1
*43.2 ± 3.3
*LM+CCl4 150 * 6 533 ± 48
*446 ± 60
*0.84 36.5 ± 5.0
*45.1 ± 3.9
*DDB+CCl4 150 * 6 276 ± 23
*288 ± 26
*1.04 39.7 ± 3.5 40.6 ± 6.5
*LD+CCl4 150 * 6 457 ± 79
*401 ± 67
*0.88 29.6 ± 3.1
*41.8 ± 3.4
*Compare with normal group: #P＜0.05, compare with group ##P＜0.01:
*P＜0.05,
*P＜0.011.2 causes the inhibitory action of mouse liver injury to thioacetamide (TAA)
Mice group, route of administration, dosage, administration number of times and consecutive days are all identical with 1.2.Except that the normal control group, all the other 6 groups after last administration in the 6th day 2 hours, weigh earlier, the dosage lumbar injection 0.2% thioacetyl amine aqueous solution by 80ml/kg makes it to poison again.Clean food is after 16 hours, and broken end is got hematometry Serum ALT and AST, gets liver and weighs, and detects LPO content, MDA content in the heavy and hepatic tissue of the liver of unit of account body weight.Result's (table 2) illustrates that thioacetamide can make transaminase activity in the mice serum and the LPO content in the hepatic tissue significantly raise, and makes the liver enlargement.And that Misgurni anguillicaudati homogenate and Misgurni anguillicaudati mucus and extract thereof all can obviously suppress in the mice serum that thioacetamide raises the LPO content regulating liver-QI in transaminase activity, the hepatic tissue is swollen.
Table 2 medicine causes inhibitory action (n=8, the group dosage Serum ALT serum AST AST/ALT liver MDA liver weight/body weight of x ± SD) of mouse liver injury to thioacetamide
/ mgkg-1 * d/UL-1/UL-1/nmolg-1/gkg-1 normal control---188 ± 47 286 ± 38 1.52 25.8 ± 3.7 35.2 ± 5.1NS+TAA 150 * 6 937 ± 22##, 693 ± 78##, 0.74 41.6 ± 2.8##, 50.8 ± 2.5##LS+TAA 150 * 6 541 ± 26
*436 ± 92
*0.81 32.6 ± 4.0
*45.9 ± 4.3
*LM+TAA 150 * 6 638 ± 14
*528 ± 18
*0.83 34.3 ± 3.5
*45.6 ± 3.2
*DDB+TAA 150 * 6 306 ± 13
*297 ± 25
*0.97 40.2 ± 3.6 45.8 ± 2.5
*LD+TAA 150 * 6 460 ± 49
*421 ± 68
*0.92 30.8 ± 3.2
*43.7 ± 4.5
*Compare with normal group: #P＜0.05, compare with group ##P＜0.01:
*P＜0.05,
*P＜0.01
It is to study hepatic effect and mechanism of action pathological model commonly used at present that carbon tetrachloride and thioacetamide cause hepatic injury.Heavy dose of attack can cause serious hepatocellular damage, causes energy metabolism impairment, and the liver plasma membrane permeability is increased, and the transaminase is released in the blood because of huge Concentraton gradient in the cell.Therefore, the serum aminotransferase activity rising is the impaired sensitive indicator of hepatocyte.Misgurni anguillicaudati homogenate is observed in this work and the Misgurni anguillicaudati mucus can both significantly suppress the caused mice serum transaminase rising of these two kinds of model things.Also observe two kinds of model things simultaneously and can both cause that lipid peroxide contents increases regulating liver-QI swelling in the murine liver tissue, Misgurni anguillicaudati homogenate and Misgurni anguillicaudati mucus can significantly suppress the rising of these indexs.As seen, Misgurni anguillicaudati and mucus thereof have many-sided inhibitory action to experimental hepatic injury.2.1 couples of carbon tetrachloride (CCl of the liver protection effect of 2 Misgurni anguillicaudati polysaccharide
4) cause the inhibitory action of mouse liver injury
40 of mices, male and female half and half, be divided into 5 groups at random: normal control group, normal saline (NS) group, Misgurni anguillicaudati polysaccharide high dose (HPS) group, Misgurni anguillicaudati polysaccharide low dosage (LPS) group and bifendate (DDB) group, gastric infusion dosage and consecutive days are undertaken by table 3.Except that the normal control group,, weigh after 2 hours in last administration in the 6th day for all the other 6 groups, make it to poison by the dosage lumbar injection 0.2% carbon tetrachloride paraffin oil solution of 10ml/kg.Clean food is after 16 hours, and broken end is got hematometry Serum ALT and AST, gets liver and weighs, and the liver of unit of account body weight is heavy.Result's (table 3) shows that carbon tetrachloride can make the transaminase activity in the mice serum significantly raise, and makes the liver enlargement.And that the Misgurni anguillicaudati polysaccharide can obviously suppress in the mice serum that carbon tetrachloride raises the transaminase activity regulating liver-QI is swollen.
Table 3 medicine causes inhibitory action (n=8, the group dosage Serum ALT serum AST AST/ALT liver weight/body weight of x ± SD) of mouse liver injury to carbon tetrachloride (CCl4)
/ mgkg-1 * d/UL-1/UL-1/gkg-1 normal control---120 ± 31 266 ± 39 2.22 35.2 ± 5.1NS+CCl4 150 * 6 727 ± 19##, 510 ± 29##, 0.70 47.2 ± 1.8##HPS+CCl4 300 * 6 352 ± 38
*347 ± 75
*0.99 42.7 ± 3.8
*LPS+CCl4 150 * 6 438 ± 21
*426 ± 74
*0.97 43.2 ± 3.3
*DDB+CCl4 150 * 6 270 ± 23
*278 ± 16
*1.03 40.6 ± 6.5
*LD+CCl4 150 * 6 457 ± 79
*401 ± 67
*0.88 41.8 ± 3.4
*Compare with normal group: #P＜0.05, compare with group ##P＜0.01:
*P＜0.05,
*P＜0.012.2 causes the inhibitory action of mouse liver injury to thioacetamide (TAA)
Mice group, route of administration, dosage, administration number of times and consecutive days are all identical with 2.1.Except that the normal control group,, weigh after 2 hours in last administration in the 6th day for all the other 6 groups, make it to poison by the dosage lumbar injection 0.2% thioacetyl amine aqueous solution of 80ml/kg.Clean food is after 16 hours, and broken end is got hematometry Serum ALT and AST, gets liver and weighs, and the liver of unit of account body weight is heavy.Result's (table 4) illustrates that thioacetamide can make the transaminase activity in the mice serum significantly raise, and makes the liver enlargement.And that the Misgurni anguillicaudati polysaccharide can obviously suppress in the mice serum that thioacetamide raises the transaminase activity regulating liver-QI is swollen.
Table 4 medicine causes inhibitory action (n=8, the group dosage Serum ALT serum AST AST/ALT liver weight/body weight of x ± SD) of mouse liver injury to thioacetamide
/ mgkg-1 * d/UL-1/UL-1/gkg-1 normal control---120 ± 31 266 ± 39 2.22 35.2 ± 5.1NS+TAA 150 * 6 737 ± 22##, 471 ± 29##, 0.64 50.8 ± 2.5##HPS+TAA 300 * 6 368 ± 15
*424 ± 18
*1.15 43.6 ± 2.2
*LPS+TAA 150 * 6 414 ± 32
*388 ± 48
*0.94 45.9 ± 4.3
*DDB+TAA 150 * 6 306 ± 13
*297 ± 25
*0.97 45.8 ± 2.5
*LD+TAA 150 * 6 460 ± 49
*421 ± 68
*0.92 43.7 ± 4.5
*Compare with normal group: #P＜0.05, compare with group ##P＜0.01:
*P＜0.05,
*P＜0.012.3 causes the inhibitory action of mouse liver injury to ANIT (NAIT)
Mice group, route of administration, dosage, administration number of times and consecutive days are all identical with 2.1.Except that the normal control group, all the other 6 groups after last administration in the 6th day 2 hours, weigh, irritate stomach 15mg/ml ANIT salad oil solution by the dosage of 80ml/kg and make it to poison.Clean food 16 hours, broken end is got hematometry Serum ALT and AST, gets liver and gall and weighs, and the liver and gall of unit of account body weight are heavy.Result's (table 5) illustrates that NAIT can make transaminase activity and icteric index in the mice serum significantly raise, and makes the liver enlargement.And the Misgurni anguillicaudati polysaccharide can suppress obviously that transaminase activity and icteric index raise in the mice serum that NAIT causes, and the liver swelling degree and the jaundice that can significantly reduce mice are smouldered.
Table 5 medicine causes inhibitory action (n=8, the group dosage Serum ALT serum AST liver weight/body weight gallbladder weight/body weight icteric index of x ± SD) of mouse liver injury to ANIT (NAIT)
/ mgkg-1 * d/UL-1/UL-1/gkg-1/gkg-1 normal control---120 ± 31 266 ± 39 35.2 ± 5.1 0.41 ± 0.12 9.3 ± 1.16NS+NAIT 150 * 6 787 ± 13##, 529 ± 9##, 49.4 ± 4.4##, 1.85 ± 0.95##, 29.5 ± 1.60##HPS+NAIT 300 * 6 319 ± 20
*353 ± 29
*45.5 ± 1.9
*0.92 ± 0.91
*15.7 ± 1.07
*LPS+NAIT 150 * 6 350 ± 32
*377 ± 26
*45.3 ± 2.1
*1.41 ± 0.90 17.8 ± 1.31
*DDB+NAIT 150 * 6 243 ± 11
*286 ± 77
*49.7 ± 6.9
*0.88 ± 0.39
*18.5 ± 1.06
*LD+NAIT 150 * 6 460 ± 49
*421 ± 68
*43.7 ± 4.5
*1.63 ± 0.97 27.3 ± 1.52 with normal group relatively: #P＜0.05, ##P＜0.01 and group relatively:
*P＜0.05,
*P＜0.01
Comprehensive The above results: making health food or therefrom extract molecular weight with Misgurni anguillicaudati is 1; 000～150; 000 natural polysaccharide, glycoprotein and polypeptides matter show that through animal experiment study it has antiinflammatory, transaminase lowering, removes jaundice and liver-protective effect.Adult's taking dose was 0.1 milligram～100 gram/days.
The preparation example:
Example 1. Misgurni anguillicaudati liver-protecting tablet: get 5～6 kilograms of fresh and alive Misgurni anguillicaudatis, fed 1 day, clean, will make 100 order fine powders with pulverizer after these Misgurni anguillicaudati dryings with clear water.Press following pharmaceutical formulation: Misgurni anguillicaudati dry powder 880 grams, starch 100 grams, sodium carboxymethyl cellulose 17.5 grams, Herba Menthae 2 grams, sodium benzoate 0.5 restrains, and after the adding distil water pelletize, is pressed into the Misgurni anguillicaudati hepatoprotective abnormity sheet of 1 gram/grain.
Example 2. Misgurni anguillicaudati HUAGAN JIAONANG: get 5～6 kilograms of fresh and alive Misgurni anguillicaudatis, fed 1 day, clean, will make 150 order fine powders with pulverizer after these Misgurni anguillicaudati dryings with clear water.Press following pharmaceutical formulation: Misgurni anguillicaudati dry powder 900 grams, starch 80 grams, sodium carboxymethyl cellulose 19.5 grams, sodium benzoate 0.5 gram after the adding distil water pelletize, incapsulates by 0.5 gram/grain, and the Misgurni anguillicaudati HUAGAN JIAONANG is made in capping.
Claims (6)
1. method for preparing functional food for protecting liver, it is characterized in that: clean with the fresh and alive Misgurni anguillicaudati that clear water was fed 1～3 day, to make 50 orders after these Misgurni anguillicaudati dryings to nano level fine powder, can be 1～98% thin dry powder of Misgurni anguillicaudati with liver-protecting function with this content, sneaking into batching and making the food that hepatoprotective becomes function.
2. method for preparing functional food for protecting liver, it is characterized in that: Misgurni anguillicaudati is twisted into the meat slurry with meat grinder, add 0～10% protease, control PH=1～8.5, in 10～50 ℃ of following incubations 5～48 hours, will make after the hydrolyzed solution drying of telling 50 orders to nano level fine powder, can be 1～98% thin dry powder of Misgurni anguillicaudati with liver-protecting function with this content, sneaking into prepares burden makes the food that hepatoprotective becomes function.
3. according to a kind of method for preparing functional food for protecting liver of claim 2 indication, it is characterized in that: described protease can be pepsin, trypsin, papain, Streptothrix protease E, protease V8 or E.C. 3.4.21.64.
4. adopt the functional food for protecting liver of Misgurni anguillicaudati preparation, it is characterized in that: the food of liver-protecting function is to be that the thin dry powder of 1～98% Misgurni anguillicaudati is as primary raw material with content, and sneak into following batching: amyloid adjuvant 1～90%, excipient and thickening agent 0～10%, flavoring agent 0～5%, vitamins 0～2%, food coloring 0～3%, edible essence 0～2%, antiseptic 0～1% is made the food of liver-protecting function.
5. according to the functional food for protecting liver of the employing Misgurni anguillicaudati of claim 4 indication preparation, it is characterized in that: said functional food for protecting liver can be special-shaped sheet, sugar pill, cookies, cake, instant noodles, oral liquid, electuary, medicated porridge is stuck with paste or the dry powder used for mixing batter.
6. according to the functional food for protecting liver of the Misgurni anguillicaudati of claim 4 indication preparation, it is characterized in that: the amyloid adjuvant of indication is: flour, starch, oatmeal, Semen Glycines powder, Rhizoma amorphophalli powder, black sesame powder, Semen arachidis hypogaeae powder; Excipient and thickening agent are: starch, dextrin, sodium carboxymethyl cellulose, agar, gelatin, alginate jelly, pectin; Flavoring agent is: Sal, sugar, Mel, milk powder, chocolate, protein sugar, cyclamate, acesulfame potassium, glucide, monosodium glutamate, chicken essence, yeastex, acetic acid, five spice powder, Fructus Piperis powder, Zanthoxyli Bungeani powder, curry powder, Fructus Capsici powder, Herba Alii fistulosi, Rhizoma Zingiberis powder, Bulbus Allii powder, Herba Menthae; Vitamins is: vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, Citrin; Food coloring is: bean sauce, soy sauce, carotene, caramel color, chocolate pigment, coffee pigment, gardenin, Fructus Citri tangerinae pigment, sunset yellow; Edible essence is: lychee flavor, apple essence, flavoring pineapple essence, strawberry essence, honey peach essence, cocoanut flavour, milk flavour, beef flavor, chicken essence, coffee aroma; Antiseptic is: benzoate, mud moor gold ester, antibacterial peptide, sorbate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00114614 CN1116047C (en) | 2000-06-05 | 2000-06-05 | Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00114614 CN1116047C (en) | 2000-06-05 | 2000-06-05 | Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03103933 Division CN1217672C (en) | 2000-06-05 | 2000-06-05 | Medicine for preventing and curing hepatitis prepared from mudlump and its preparing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1293041A CN1293041A (en) | 2001-05-02 |
| CN1116047C true CN1116047C (en) | 2003-07-30 |
Family
ID=4584267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00114614 Expired - Fee Related CN1116047C (en) | 2000-06-05 | 2000-06-05 | Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1116047C (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897404B (en) * | 2010-05-25 | 2013-04-24 | 湖南农业大学 | Preparation method of loach dried noodles |
| CN101946895B (en) * | 2010-09-02 | 2012-06-27 | 山东商业职业技术学院 | Functional food taking loach as main material and preparation method thereof |
| ES2705950T3 (en) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds |
| CN102771704A (en) * | 2012-06-18 | 2012-11-14 | 胡侠 | Special loach noodles for arthritis patients and manufacture method of special loach noodles |
| MX368099B (en) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds. |
| CN103394071B (en) * | 2013-07-29 | 2015-06-03 | 四川龙王洞生态农业开发有限公司 | Method for producing giant salamander polypeptide powder liver protection capsules |
| JO3783B1 (en) | 2014-08-28 | 2021-01-31 | Eisai R&D Man Co Ltd | Highly pure quinoline derivative and method for producing the same |
| CN104738700B (en) * | 2015-02-16 | 2017-11-21 | 湖南鳅祥生物科技实业有限公司 | A kind of loach protect liver product and preparation method thereof |
| DK3263106T3 (en) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | PROCESS FOR SUPPRESSING BITTERNESS OF QUINOLINE DERIVATIVES |
| CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| CN107801379B (en) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | Anticancer agent |
| CN108576825A (en) * | 2018-04-11 | 2018-09-28 | 崔勇 | A kind of loach protein powder and the preparation method and application thereof, for reducing the food and drug of blood fat or cholesterol or blood pressure |
| CN112587647B (en) * | 2020-12-22 | 2023-02-17 | 中国海洋大学 | Application of fish egg glycoprotein in liver protection product |
-
2000
- 2000-06-05 CN CN 00114614 patent/CN1116047C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1293041A (en) | 2001-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1116047C (en) | Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process | |
| US10278994B2 (en) | Method for the preparation of skipjack tuna extract having uric acid-lowering effect and the use thereof | |
| KR102204299B1 (en) | Therapeutic agent for coronavirus comprising Elaeocarpus sylvestris extract as effective component | |
| CN101119738B (en) | Herbal mixture extract of notoginseng radix, rehmanniae radix preparata and acanthopanacis cortex and composition comprising the same for prevention and treatment of arthritis | |
| GB2503628A (en) | Pharmaceutical compostion for controlling blood sugar, blood lipid and body weight | |
| US20190076496A1 (en) | Polysaccharide digestion inhibitor | |
| WO2005072758A1 (en) | Composition comprising hovenia dulcis thunb. extract, lindera obtusiloba blume extract, or herbal mixture extract thereof | |
| CN101433595A (en) | Desertliving cistanche alcohol extract as well as preparation method and use thereof | |
| CN109498659B (en) | Application of sandworm zymolyte in preparation of osteoarthritis prevention and treatment medicines or health-care products | |
| CN1217672C (en) | Medicine for preventing and curing hepatitis prepared from mudlump and its preparing | |
| WO2014134833A1 (en) | Edible composition, preparation method therefor, and food product comprising the composition | |
| CN107050090A (en) | The effect of beneficial liver and its application of high mountain horseradish dish | |
| CN1128632C (en) | Traditional Chinese medicine compound preparation for treating chronic hepatitis B and preparation process thereof | |
| JP2022511544A (en) | Chinese herbal medicine composition for bowel movement, its preparation method and its use | |
| KR20050014615A (en) | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis | |
| CN110801456A (en) | Application of cordycepin in preparation of liver protection product | |
| CN104000969B (en) | A kind of Chinese materia medica preparation for treating children's intestines system lymphonodi abdominales inflammation | |
| CN103211906A (en) | Medicinal food used for viral diarrhea | |
| CN100574798C (en) | The preparation method of the medicine of treatment chronic incomplete renal function | |
| KR101954890B1 (en) | A composition for treating or improving non-alcoholic fatty liver disease comprising Seahorse extract | |
| JP2023035438A (en) | Depressant of rise in blood glucose level | |
| CN117919359A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating acute pancreatitis | |
| CN1108164C (en) | Freshly squeezing and shadily drying process to prepare Chinese herbal medicine pieces | |
| CN105998152A (en) | Dioscorea opposita Thunb. with liver benefiting effect and application thereof | |
| KR101030566B1 (en) | Composition for Treatment of Liver Fibrosis and Liver Cirrhosis Comprising Betaine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |